Cellular-based immunotherapies for patients with glioblastoma multiforme

Clinical and Developmental Immunology

Volumn 2012, Issue , 2012, Pages

  Xu, Xun ^a   Stockhammer, Florian ^b   Schmitt, Michael ^c  

^a Institute of Polymer Research   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BEVACIZUMAB; GLIOBLASTOMA ASSOCIATED ANTIGEN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; CANCER VACCINE; CELL EXTRACT; CYTOKINE; DACARBAZINE; DRUG DERIVATIVE;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; AUTOLOGOUS TUMOR CELL; CANCER IMMUNOTHERAPY; CANCER SURGERY; DENDRITIC CELL; GLIOBLASTOMA; HUMAN; MULTIPLE CYCLE TREATMENT; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; RECURRENT CANCER; REGULATORY T LYMPHOCYTE; REVIEW; SUPPRESSOR CELL; TH17 CELL; TUMOR CELL; AGED; BRAIN TUMOR; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY;

AGED; BRAIN NEOPLASMS; CANCER VACCINES; CELL EXTRACTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CYTOKINES; DACARBAZINE; DENDRITIC CELLS; GLIOBLASTOMA; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY; MIDDLE AGED;

EID: 84863270634     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2012/764213     Document Type: Review

References (153)

1. Fleury A., Menegoz F., Grosclaude P., Descriptive epidemiology of cerebral gliomas in France Cancer 1997 79 6 1195 1202 (Pubitemid 27118217)
2. Mirimanoff R. O., Gorlia T., Mason W., Van Den Bent M. J., Kortmann R. D., Fisher B., Reni M., Brandes A. A., Curschmann J., Villa S., Cairncross G., Allgeier A., Lacombe D., Stupp R., Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial Journal of Clinical Oncology 2006 24 16 2563 2569 (Pubitemid 46630635)
3. Stummer W., Reulen H. J., Meinel T., Pichlmeier U., Schumacher W., Tonn J. C., Rohde V., Oppel F., Turowski B., Woiciechowsky C., Franz K., Pietsch T., Oppel F., Brune A., Lanksch W., Woiciechowsky C., Brock M., Vesper J., Tonn J. C., Goetz C., Gilsbach J. M., Mayfrank L., Oertel M. F., Seifert V., Franz K., Bink A. J. W., Schackert G., Pinzer T., Hassler W., Bani A., Meisel H. J., Kern B. C., Mehdorn H. M., Nabavi A., Brawanski A., Ullrich O. W., Bker D. K., Winking M., Weber F., Langenbach U., Westphal M., Khler U., Arnold H., Knopp U., Grumme T., Stretz T., Stolke D., Wiedemayer H., Turowski B., Pietsch T., Wiestler O. D., Reulen H. J., Stummer W., Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias Neurosurgery 2008 62 3 564 576
4. Stummer W., Pichlmeier U., Meinel T., Wiestler O. D., Zanella F., Reulen H. J., Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial The Lancet Oncology 2006 7 5 392 401
5. Stockhammer F., Misch M., Horn P., Koch A., Fonyuy N., Plotkin M., Association of F18-fluoro-ethyl-tyrosin uptake and 5-aminolevulinic acid-induced fluorescence in gliomas Acta Neurochirurgica 2009 151 11 1377 1383
6. Westphal M., Ram Z., Riddle V., Hilt D., Bortey E., Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial Acta Neurochirurgica 2006 148 3 269 275 (Pubitemid 43341024)
7. Menei P., Metellus P., Parot-Schinkel E., Loiseau H., Capelle L., Jacquet G., Guyotat J., Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience Annals of Surgical Oncology 2010 17 7 1740 1746
8. Kreth F. W., Warnke P. C., Scheremet R., Ostertag C. B., Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme Journal of Neurosurgery 1993 78 5 762 766 (Pubitemid 23121918)
9. Kreth F. W., Muacevic A., Medele R., Bise K., Meyer T., Reulen H. J., The risk of haemorrhage after image guided stereotactic biopsy of intra-axial brain tumoursa prospective study Acta Neurochirurgica 2001 143 6 539 546 (Pubitemid 32662388)
10. Grasbon-Frodl E. M., Kreth F. W., Ruiter M., Schnell O., Bise K., Felsberg J., Reifenberger G., Tonn J. C., Kretzschmar H. A., Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas International Journal of Cancer 2007 121 11 2458 2464 (Pubitemid 350022415)
11. Stupp R., Mason W. P., Van Den Bent M. J., Weller M., Fisher B., Taphoorn M. J. B., Belanger K., Brandes A. A., Marosi C., Bogdahn U., Curschmann J., Janzer R. C., Ludwin S. K., Gorlia T., Allgeier A., Lacombe D., Cairncross J. G., Eisenhauer E., Mirimanoff R. O., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma The New England Journal of Medicine 2005 352 10 987 996 (Pubitemid 40349501)
12. Stupp R., Hegi M. E., Mason W. P., van den Bent M. J., Taphoorn M. J., Janzer R. C., Ludwin S. K., Allgeier A., Fisher B., Belanger K., Hau P., Brandes A. A., Gijtenbeek J., Marosi C., Vecht C. J., Mokhtari K., Wesseling P., Villa S., Eisenhauer E., Gorlia T., Weller M., Lacombe D., Cairncross J. G., Mirimanoff R. O., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial The Lancet Oncology 2009 10 5 459 466
13. Hegi M. E., Diserens A. C., Gorlia T., Hamou M. F., De Tribolet N., Weller M., Kros J. M., Hainfellner J. A., Mason W., Mariani L., Bromberg J. E. C., Hau P., Mirimanoff R. O., Cairncross J. G., Janzer R. C., Stupp R., MGMT gene silencing and benefit from temozolomide in glioblastoma The New England Journal of Medicine 2005 352 10 997 1003 (Pubitemid 40349502)
14. Hau P., Koch D., Hundsberger T., Marg E., Bauer B., Rudolph R., Rauch M., Brenner A., Rieckmann P., Schuth J., Jauch T., Koch H., Bogdahn U., Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma Neurology 2007 68 9 688 690 (Pubitemid 46667817)
15. Barbagallo G. M. V., Jenkinson M. D., Brodbelt A. R., 'Recurrent' glioblastoma multiforme, when should we reoperate? British Journal of Neurosurgery 2008 22 3 452 455 (Pubitemid 351878614)
16. Mandl E. S., Dirven C. M. F., Buis D. R., Postma T. J., Vandertop W. P., Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy Surgical Neurology 2008 69 5 506 509
17. Combs S. E., Bischof M., Welzel T., Hof H., Oertel S., Debus J., Schulz-Ertner D., Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas Journal of Neuro-Oncology 2008 89 2 205 210
18. Villavicencio A. T., Burneikiene S., Romanelli P., Fariselli L., McNeely L., Lipani J. D., Chang S. D., Nelson E. L., McIntyre M., Broggi G., Adler J. R., Survival following stereotactic radiosurgery for newly diagnosed and recurrent glioblastoma multiforme: a multicenter experience Neurosurgical Review 2009 32 4 417 424
19. Cloughesy T., FDA accelerated approval benefits glioblastoma The Lancet Oncology 2010 11 12 1120
20. Vredenburgh J. J., Desjardins A., Herndon J. E., Dowell J. M., Reardon D. A., Quinn J. A., Rich J. N., Sathornsumetee S., Gururangan S., Wagner M., Bigner D. D., Friedman A. H., Friedman H. S., Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Clinical Cancer Research 2007 13 4 1253 1259 (Pubitemid 46424067)
21. Vredenburgh J. J., Desjardins A., Herndon J. E., Marcello J., Reardon D. A., Quinn J. A., Rich J. N., Sathornsumetee S., Gururangan S., Sampson J., Wagner M., Bailey L., Bigner D. D., Friedman A. H., Friedman H. S., Bevacizumab plus irinotecan in recurrent glioblastoma multiforme Journal of Clinical Oncology 2007 25 30 4722 4729 (Pubitemid 350086473)
22. Friedman H. S., Prados M. D., Wen P. Y., Mikkelsen T., Schiff D., Abrey L. E., Yung W. K. A., Paleologos N., Nicholas M. K., Jensen R., Vredenburgh J., Huang J., Zheng M., Cloughesy T., Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma Journal of Clinical Oncology 2009 27 28 4733 4740
23. Brandes A. A., Tosoni A., Cavallo G., Bertorelle R., Gioia V., Franceschi E., Biscuola M., Blatt V., Crin L., Ermani M., Temozolomide 3weeks on and 1week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) British Journal of Cancer 2006 95 9 1155 1160 (Pubitemid 44658477)
24. Wick A., Felsberg J., Steinbach J. P., Herrlinger U., Platten M., Blaschke B., Meyermann R., Reifenberger G., Weller M., Wick W., Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma Journal of Clinical Oncology 2007 25 22 3357 3361 (Pubitemid 47325623)
25. Perry J. R., Rizek P., Cashman R., Morrison M., Morrison T., Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach Cancer 2008 113 8 2152 2157
26. Stockhammer F., Misch M., Koch A., Czabanka M., Plotkin M., Blechschmidt C., Tuettenberg J., Vajkoczy P., Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma Journal of Neuro-Oncology 2010 100 3 407 415
27. Hau P., Baumgart U., Pfeifer K., Bock A., Jauch T., Dietrich J., Fabel K., Grauer O., Wismeth C., Klinkhammer-Schalke M., Allguer M., Schuierer G., Koch H., Schlaier J., Ulrich W., Brawanski A., Bogdahn U., Steinbrecher A., Salvage therapy in patients with glioblastoma: is there any benefit? Cancer 2003 98 12 2678 2686 (Pubitemid 37509533)
28. Hong S., Van Kaer L., Immune privilege: keeping an eye on natural killer T cells The Journal of Experimental Medicine 1999 190 9 1197 1200 (Pubitemid 29522204)
29. Kanaly C. W., Ding D., Heimberger A. B., Sampson J. H., Clinical applications of a peptide-based vaccine for glioblastoma Neurosurgery Clinics of North America 2010 21 1 95 109
30. Thara E., Dorff T. B., Pinski J. K., Quinn D. I., Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer Maturitas 2011 69 4 296 303
31. Jacobs S. K., Wilson D. J., Kornblith P. L., Grimm E. A., Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial Cancer Research 1986 46 4 2101 2104 (Pubitemid 16117915)
32. Merchant R. E., Grant A. J., Merchant L. H., Young H. F., Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2 Cancer 1988 62 4 665 671
33. Barba D., Saris S. C., Holder C., Rosenberg S. A., Oldfield E. H., Intratumoral LAK cell and interleukin-2 therapy of human gliomas Journal of Neurosurgery 1989 70 2 175 182 (Pubitemid 19051711)
34. Lillehei K. O., Mitchell D. H., Johnson S. D., McCleary E. L., Kruse C. A., Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy Neurosurgery 1991 28 1 16 23
35. Jeffes E. W. B. III, Beamer Y. B., Jacques S., Silberman R. S., Vayuvegula B., Gupta S., Coss J. S., Yamamoto R. S., Granger G. A., Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA Journal of Neuro-Oncology 1993 15 2 141 155 (Pubitemid 23136029)
36. Blancher A., Roubinet F., Grancher A. S., Tremoulet M., Bonate A., Delisle M. B., Calot J. P., Pourreau C., Franks C., Ducos J., Rascol A., Clanet M., Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells European Cytokine Network 1993 4 5 331 341 (Pubitemid 24001545)
37. Boiardi A., Silvani A., Adelchi Ruffini P., Rivoltini L., Parmiani G., Broggi G., Salmaggi A., Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients Cancer Immunology Immunotherapy 1994 39 3 193 197 (Pubitemid 24298394)
38. Hayes R. L., Koslow M., Hiesiger E. M., Hymes K. B., Hochster H. S., Moore E. J., Pierz D. M., Chen D. K., Budzilovich G. N., Ransohoff J., Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma Cancer 1995 76 5 840 852
39. Sankhla S. K., Nadkarni J. S., Bhagwati S. N., Adoptive immimotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrentmalignant primary brain tumors Journal of Neuro-Oncology 1995 27 2 133 140
40. Hayes R. L., Arbit E., Odaimi M., Pannullo S., Scheff R., Kravchinskiy D., Zaroulis C., Adoptive cellular immunotherapy for the treatment of malignant gliomas Critical Reviews in Oncology/Hematology 2001 39 1-2 31 42 (Pubitemid 32551987)
41. Dillman R. O., Duma C. M., Schiltz P. M., DePriest C., Ellis R. A., Okamoto K., Beutel L. D., De Leon C., Chico S., Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma Journal of Immunotherapy 2004 27 5 398 404 (Pubitemid 39121929)
42. Dillman R. O., Duma C. M., Ellis R. A., Cornforth A. N., Schiltz P. M., Sharp S. L., Depriest M. C., Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma Journal of Immunotherapy 2009 32 9 914 919
43. Holladay F. P., Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with Grade III/IV astrocytoma Journal of Neuro-Oncology 1996 27 2 179 189 (Pubitemid 26052654)
44. Plautz G. E., Barnett G. H., Miller D. W., Cohen B. H., Prayson R. A., Krauss J. C., Luciano M., Kangisser D. B., Shu S., Systemic T cell adoptive immunotherapy of malignant gliomas Journal of Neurosurgery 1998 89 1 42 51 (Pubitemid 28285921)
45. Plautz G. E., Miller D. W., Barnett G. H., Stevens G. H. J., Maffett S., Kim J., Cohen P. A., Shu S., T cell adoptive immunotherapy of newly diagnosed gliomas Clinical Cancer Research 2000 6 6 2209 2218 (Pubitemid 30399186)
46. Wood G. W., Holladay F. P., Turner T., Wang Y. Y., Chiga M., A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma Journal of Neuro-Oncology 2000 48 2 113 120
47. Sloan A. E., Dansey R., Zamorano L., Barger G., Hamm C., Diaz F., Baynes R., Wood G., Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes Neurosurgical Focus 2000 9 6 e9
48. Kruse C. A., Cepeda L., Owens B., Johnson S. D., Stears J., Lillehei K. O., Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2 Cancer Immunology Immunotherapy 1997 45 2 77 87 (Pubitemid 27497682)
49. Quattrocchi K. B., Miller C. H., Cush S., Bernard S. A., Dull S. T., Smith M., Gudeman S., Varia M. A., Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas Journal of Neuro-Oncology 1999 45 2 141 157 (Pubitemid 30197728)
50. Kronik N., Kogan Y., Vainstein V., Agur Z., Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics Cancer Immunology, Immunotherapy 2008 57 3 425 439 (Pubitemid 50007307)
51. Sobol R. E., Fakhrai H., Shawler D., Gjerset R., Dorigo O., Carson C., Khaleghi T., Koziol J., Shiftan T. A., Royston I., Interleukin-2 gene therapy in a patient with glioblastoma Gene Therapy 1995 2 2 164 167
52. Schneider T., Gerhards R., Kirches E., Firsching R., Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme Journal of Neuro-Oncology 2001 53 1 39 46 (Pubitemid 32936658)
53. Andrews D. W., Resnicoff M., Flanders A. E., Kenyon L., Curtis M., Merli G., Baserga R., Iliakis G., Aiken R. D., Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas Journal of Clinical Oncology 2001 19 8 2189 2200 (Pubitemid 32366973)
54. Okada H., Lieberman F. S., Edington H. D., Witham T. F., Wargo M. J., Cai Q., Elder E. H., Whiteside T. L., Schold S. C., Pollack I. F., Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy Journal of Neuro-Oncology 2003 64 1-2 13 20 (Pubitemid 36992456)
55. Steiner H. H., Bonsanto M. M., Beckhove P., Brysch M., Geletneky K., Ahmadi R., Schuele-Freyer R., Kremer P., Ranaie G., Matejic D., Bauer H., Kiessling M., Kunze S., Schirrmacher V., Herold-Mende C., Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefits Journal of Clinical Oncology 2004 22 21 4272 4281 (Pubitemid 41185148)
56. Parney I. F., Chang L. J., Farr-Jones M. A., Hao C., Smylie M., Petruk K. C., Technical hurdles in a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for glioblastomas and melanomas Journal of Neuro-Oncology 2006 78 1 71 80 (Pubitemid 43786663)
57. Ishikawa E., Tsuboi K., Yamamoto T., Muroi A., Takano S., Enomoto T., Matsumura A., Ohno T., Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients Cancer Science 2007 98 8 1226 1233 (Pubitemid 46993543)
58. Clavreul A., Piard N., Tanguy J. Y., Gamelin E., Rousselet M. C., Leynia P., Menei P., Autologous tumor cell vaccination plus infusion of GM-CSF by a programmable pump in the treatment of recurrent malignant gliomas Journal of Clinical Neuroscience 2010 17 7 842 848
59. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y. J., Pulendran B., Palucka K., Immunobiology of dendritic cells Annual Review of Immunology 2000 18 767 811 (Pubitemid 30365397)
60. Steinman R. M., Banchereau J., Taking dendritic cells into medicine Nature 2007 449 7161 419 426 (Pubitemid 47509552)
61. Okada H., Kalinski P., Ueda R., Induction of CD8 + T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with -type 1 polarized dendritic cells and polyinosinic- polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma Journal of Clinical Oncology 2011 29 3 330 336
62. Prins R. M., Soto H., Konkankit V., Odesa S. K., Eskin A., Yong W. H., Nelson S. F., Liau L. M., Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy Clinical Cancer Research 2011 17 6 1603 1615
63. Ardon H., Van Gool S., Lopes I. S., Maes W., Sciot R., Wilms G., Demaerel P., Bijttebier P., Claes L., Goffin J., Van Calenbergh F., De Vleeschouwer S., Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study Journal of Neuro-Oncology 2010 99 2 261 272
64. Ardon H., De Vleeschouwer S., Van Calenbergh F., Claes L., Kramm C. M., Rutkowski S., Wolff J. E. A., Van Gool S. W., Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours Pediatric Blood and Cancer 2010 54 4 519 525
65. Sampson J. H., Archer G. E., Mitchell D. A., Heimberger A. B., Herndon J. E., Lally-Goss D., McGehee-Norman S., Paolino A., Reardon D. A., Friedman A. H., Friedman H. S., Bigner D. D., An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme Molecular Cancer Therapeutics 2009 8 10 2773 2779
66. De Vleeschouwer S., Fieuws S., Rutkowski S., Van Calenbergh F., Van Loon J., Goffin J., Sciot R., Wilms G., Demaerel P., Warmuth-Metz M., Soerensen N., Wolff J. E. A., Wagner S., Kaempgen E., Van Gool S. W., Postoperative adjuvant dendritic cellbased immunotherapy in patients with relapsed glioblastoma multiforme Clinical Cancer Research 2008 14 10 3098 3104
67. Wheeler C. J., Black K. L., Liu G., Mazer M., Zhang X. X., Pepkowitz S., Goldfinger D., Ng H., Irvin D., Yu J. S., Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients Cancer Research 2008 68 14 5955 5964
68. Yamanaka R., Homma J., Yajima N., Tsuchiya N., Sano M., Kobayashi T., Yoshida S., Abe T., Narita M., Takahashi M., Tanaka R., Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial Clinical Cancer Research 2005 11 11 4160 4167 (Pubitemid 40791581)
69. Liau L. M., Prins R. M., Kiertscher S. M., Odesa S. K., Kremen T. J., Giovannone A. J., Lin J. W., Chute D. J., Mischet P. S., Cloughesy T. F., Roth M. D., Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment Clinical Cancer Research 2005 11 15 5515 5525 (Pubitemid 41060828)
70. Yu J. S., Liu G., Ying H., Yong W. H., Black K. L., Wheeler C. J., Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma Cancer Research 2004 64 14 4973 4979 (Pubitemid 38924545)
71. Kikuchi T., Akasaki Y., Abe T., Fukuda T., Saotome H., Ryan J. L., Kufe D. W., Ohno T., Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12 Journal of Immunotherapy 2004 27 6 452 459 (Pubitemid 39447353)
72. Caruso D. A., Orme L. M., Neale A. M., Radcliff F. J., Armor G. M., Maixner W., Downie P., Hassall T. E., Tang M. L. K., Ashley D. M., Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer Neuro-Oncology 2004 6 3 236 246 (Pubitemid 39136507)
73. Wheeler C. J., Das A., Liu G., Yu J. S., Black K. L., Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination Clinical Cancer Research 2004 10 16 5316 5326 (Pubitemid 39100466)
74. Yamanaka R., Abe T., Yajima N., Tsuchiya N., Homma J., Kobayashi T., Narita M., Takahashi M., Tanaka R., Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial British Journal of Cancer 2003 89 7 1172 1179 (Pubitemid 37363398)
75. Yu J. S., Wheeler C. J., Zeltzer P. M., Ying H., Finger D. N., Lee P. K., Yong W. H., Incardona F., Thompson R. C., Riedinger M. S., Zhang W., Prins R. M., Black K. L., Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration Cancer Research 2001 61 3 842 847 (Pubitemid 32175145)
76. Wheeler C. J., Black K. L., Liu G., Thymic CD8 + T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality The Journal of Immunology 2003 171 9 4927 4933 (Pubitemid 37310617)
77. Tuyaerts S., Aerts J. L., Corthals J., Neyns B., Heirman C., Breckpot K., Thielemans K., Bonehill A., Current approaches in dendritic cell generation and future implications for cancer immunotherapy Cancer Immunology, Immunotherapy 2007 56 10 1513 1537 (Pubitemid 47094397)
78. Okada H., Lieberman F. S., Walter K. A., Lunsford L. D., Kondziolka D. S., Bejjani G. K., Hamilton R. L., Torres-Trejo A., Kalinski P., Cai Q., Mabold J. L., Edington H. D., Butterfield L. H., Whiteside T. L., Potter D. M., Schold S. C., Pollack I. F., Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas Journal of Translational Medicine 2007 5, article 67
79. Kogiku M., Ohsawa I., Matsumoto K., Sugisaki Y., Takahashi H., Teramoto A., Ohta S., Prognosis of glioma patients by combined immunostaining for survivin, Ki-67 and epidermal growth factor receptor Journal of Clinical Neuroscience 2008 15 11 1198 1203
80. Rosenberg S. A., Cancer vaccines based on the identification of genes encoding cancer regression antigens Immunology Today 1997 18 4 175 182 (Pubitemid 27192179)
81. Wang R. F., The role of MHC class II-restricted tumor antigens and CD4 + T cells in antitumor immunity Trends in Immunology 2001 22 5 269 276
82. Fernandez N. C., Lozier A., Flament C., Ricciardi-Castagnoli P., Bellet D., Suter M., Perricaudet M., Tursz T., Maraskovsky E., Zitvogel L., Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo Nature Medicine 1999 5 4 405 411 (Pubitemid 29180578)
83. Wehner R., Lbel B., Bornhuser M., Schkel K., Cartellieri M., Bachmann M., Rieber E. P., Schmitz M., Reciprocal activating interaction between 6-sulfo LacNAc + dendritic cells and NK cell International Journal of Cancer 2009 124 2 358 366
84. Schmitz M., Zhao S., Deuse Y., Schkel K., Wehner R., Whner H., Hlig K., Wienforth F., Kiessling A., Bornhuser M., Temme A., Rieger M. A., Weigle B., Bachmann M., Rieber E. P., Tumoricidal potential of native blood dendritic cells: direct tumor cell killing and activation of NK cell-mediated cytotoxicity The Journal of Immunology 2005 174 7 4127 4134 (Pubitemid 40395990)
85. Fadul C. E., Fisher J. L., Hampton T. H., Lallana E. C., Li Z., Gui J., Szczepiorkowski Z. M., Tosteson T. D., Rhodes C. H., Wishart H. A., Lewis L. D., Ernstoff M. S., Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy Journal of Immunotherapy 2011 34 4 382 389
86. Hatano M., Eguchi J., Tatsumi T., Kuwashima N., Dusak J. E., Kinch M. S., Pollack I. F., Hamilton R. L., Storkus W. J., Okada H., EphA2 as a glioma-associated antigen: a novel target for glioma vaccines Neoplasia 2005 7 8 717 722
87. Schmitz M., Wehner R., Stevanovic S., Kiessling A., Rieger M. A., Temme A., Bachmann M., Rieber E. P., Weigle B., Identification of a naturally processed T cell epitope derived from the glioma-associated protein SOX11 Cancer Letters 2007 245 1-2 331 336 (Pubitemid 44959365)
88. Liu G., Ying H., Zeng G., Wheeler C. J., Black K. L., Yu J. S., HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells Cancer Research 2004 64 14 4980 4986 (Pubitemid 38924546)
89. Saikali S., Avril T., Collet B., Hamlat A., Bansard J. Y., Drenou B., Guegan Y., Quillien V., Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13R 2, gp100 and TRP-2 for immunotherapy Journal of Neuro-Oncology 2007 81 2 139 148 (Pubitemid 44963972)
90. Okada H., Kohanbash G., Zhu X., Kastenhuber E. R., Hoji A., Ueda R., Fujita M., Immunotherapeutic approaches for glioma Critical Reviews in Immunology 2009 29 1 1 42
91. Ueda R., Low K. L., Zhu X., Fujita M., Sasaki K., Whiteside T. L., Butterfield L. H., Okada H., Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma Journal of Translational Medicine 2007 5, article 68
92. Zhang J. G., Kruse C. A., Driggers L., Hoa N., Wisoff J., Allen J. C., Zagzag D., Newcomb E. W., Jadus M. R., Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy Journal of Neuro-Oncology 2008 88 1 65 76
93. Scarcella D. L., Chow C. W., Gonzales M. F., Economou C., Brasseur F., Ashley D. M., Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers Clinical Cancer Research 1999 5 2 335 341 (Pubitemid 29085187)
94. Bao L., Dunham K., Lucas K., MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing Cancer Immunology, Immunotherapy 2011 60 9 1299 1307
95. Jian G. Z., Eguchi J., Kruse C. A., Gomez G. G., Fakhrai H., Schroter S., Ma W., Hoa N., Minev B., Delgado C., Wepsic H. T., Okada H., Jadus M. R., Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics Clinical Cancer Research 2007 13 2 566 575 (Pubitemid 46225363)
96. Liu G., Yu J. S., Zeng G., Yin D., Xie D., Black K. L., Ying H., AIM-2: a novel tumor antigen is expressed and presented by human glioma cells Journal of Immunotherapy 2004 27 3 220 226 (Pubitemid 39118086)
97. Driggers L., Zhang J. G., Newcomb E. W., Ge L., Hoa N., Jadus M. R., Immunotherapy of pediatric brain tumor patients should include an immunoprevention strategy: a medical hypothesis paper Journal of Neuro-Oncology 2010 97 2 159 169
98. Xu Q., Liu G., Yuan X., Xu M., Wang H., Ji J., Konda B., Black K. L., Yu J. S., Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens Stem Cells 2009 27 8 1734 1740
99. Abdouh M., Facchino S., Chatoo W., Balasingam V., Ferreira J., Bernier G., BMI1 sustains human glioblastoma multiforme stem cell renewal The Journal of Neuroscience 2009 29 28 8884 8896
100. Shono T., Tofilon P. J., Bruner J. M., Owolabi O., Lang F. F., Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations Cancer Research 2001 61 11 4375 4381 (Pubitemid 32685762)
101. Orzan F., Pellegatta S., Poliani P. L., Pisati F., Caldera V., Menghi F., Kapetis D., Marras C., Schiffer D., Finocchiaro G., Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells Neuropathology and Applied Neurobiology 2011 37 4 381 394
102. Cheng L., Wu Q., Guryanova O. A., Huang Z., Huang Q., Rich J. N., Bao S., Elevated invasive potential of glioblastoma stem cells Biochemical and Biophysical Research Communications 2011 406 4 643 648
103. Jin F., Zhao L., Guo Y. J., Zhao W. J., Zhang H., Wang H. T., Shao T., Zhang S. L., Wei Y. J., Feng J., Jiang X. B., Zhao H. Y., Influence of Etoposide on anti-apoptotic and multidrug resistance-associated protein genes in CD133 positive U251 glioblastoma stem-like cells Brain Research 2010 1336 103 111
104. Kuan C. T., Wakiya K., Herndon J. E., Lipp E. S., Pegram C. N., Riggins G. J., Rasheed A., Szafranski S. E., McLendon R. E., Wikstrand C. J., Bigner D. D., MRP3: a molecular target for human glioblastoma multiforme immunotherapy BMC Cancer 2010 10, article 468
105. Ishiwata T., Teduka K., Yamamoto T., Kawahara K., Matsuda Y., Naito Z., Neuroepithelial stem cell marker nestin regulates the migration, invasion and growth of human gliomas Oncology Reports 2011 26 1 91 99
106. Ligon K. L., Alberta J. A., Kho A. T., Weiss J., Kwaan M. R., Nutt C. L., Louis D. N., Stiles C. D., Rowitch D. H., The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas Journal of Neuropathology and Experimental Neurology 2004 63 5 499 509 (Pubitemid 38669670)
107. Annovazzi L., Mellai M., Caldera V., Valente G., Schiffer D., SOX2 expression and amplification in gliomas and glioma cell lines Cancer Genomics and Proteomics 2011 8 3 139 147
108. Kakino S., Sasaki K., Kurose A., Ito H., Intracellular localization of cyclin B1 during the cell cycle in glioma cells Cytometry 1996 24 1 49 54 (Pubitemid 26169928)
109. Rossi M., Magnoni L., Miracco C., Mori E., Tosi P., Pirtoli L., Tini P., Oliveri G., Cosci E., Bakker A., -catenin and Gli1 are prognostic markers in glioblastoma Cancer Biology and Therapy 2011 11 8 753 761
110. Cui D., Xu Q., Wang K., Che X., Gli1 is a potential target for alleviating multidrug resistance of gliomas Journal of the Neurological Sciences 2010 288 1-2 156 166
111. Senetta R., Miracco C., Lanzafame S., Chiusa L., Caltabiano R., Galia A., Stella G., Cassoni P., Epidermal growth factor receptor and caveolin-1 coexpression identifies adult supratentorial ependymomas with rapid unfavorable outcomes Neuro-Oncology 2011 13 2 176 183
112. Sivaparvathi M., Sawaya R., Wang S. W., Rayford A., Yamamoto M., Liotta L. A., Nicolson G. L., Rao J. S., Overexpression and localization of cathepsin B during the progression of human gliomas Clinical and Experimental Metastasis 1995 13 1 49 56
113. Kitange G. J., Carlson B. L., Schroeder M. A., Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance Journal of Neuro-Oncology 2010 100 2 177 186
114. Lewis-Tuffin L. J., Rodriguez F., Giannini C., Scheithauer B., Necela B. M., Sarkaria J. N., Anastasiadis P. Z., Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype PLoS ONE 2010 5 10
115. Wykosky J., Gibo D. M., Stanton C., Debinski W., EphA2 as a novel molecular marker and target in glioblastoma multiforme Molecular Cancer Research 2005 3 10 541 551 (Pubitemid 41567273)
116. Wykosky J., Gibo D. M., Stanton C., Debinski W., Interleukin-13 receptor 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy Clinical Cancer Research 2008 14 1 199 208 (Pubitemid 351377996)
117. Mennel H. D., Lell B., Ganglioside (GD2) expression and intermediary filaments in astrocytic tumors Clinical Neuropathology 2005 24 1 13 18 (Pubitemid 40128782)
118. Yamamoto H., Swoger J., Greene S., Saito T., Hurh J., Sweeley C., Leestma J., Mkrdichian E., Cerullo L., Nishikawa A., Ihara Y., Taniguchi N., Moskal J. R., 1,6-N-acethylglucosamine-bearing N-glycans in human gliomas: implications for a role in regulating invasivity Cancer Research 2000 60 1 134 142 (Pubitemid 30058743)
119. Persson O., Salford L. G., Fransson J., Widegren B., Borrebaeck C. A. K., Holmqvist B., Distribution, cellular localization, and therapeutic potential of the tumor-associated antigen Ku70/80 in glioblastoma multiforme Journal of Neuro-Oncology 2010 97 2 207 215
120. Elsir T., Eriksson A., Orrego A., Lindstrm M. S., Nistér M., Expression of PROX1 is a common feature of high-grade malignant astrocytic gliomas Journal of Neuropathology and Experimental Neurology 2010 69 2 129 138
121. Geiger K. D., Hendruschk S., Rieber E. P., Morgenroth A., Weigle B., Juratli T., Senner V., Schackert G., Temme A., The prostate stem cell antigen represents a novel glioma-associated antigen Oncology Reports 2011 26 1 13 21
122. Ferletta M., Uhrbom L., Olofsson T., Pontén F., Westermark B., Sox10 has a broad expression pattern in gliomas and enhances platelet-derived growth factor-Binduced gliomagenesis Molecular Cancer Research 2007 5 9 891 897 (Pubitemid 47416666)
123. Gondi C. S., Lakka S. S., Dinh D. H., Olivero W. C., Gujrati M., Rao J. S., RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas Oncogene 2004 23 52 8486 8496 (Pubitemid 39540799)
124. Gomez G. G., Kruse C. A., Mechanisms of malignant glioma immune resistance and sources of immunosuppression Gene Therapy and Molecular Biology 2006 10 1 133 146 (Pubitemid 351976185)
125. Cobbs C. S., Harkins L., Samanta M., Gillespie G. Y., Bharara S., King P. H., Nabors L. B., Cobbs C. G., Britt W. J., Human cytomegalovirus infection and expression in human malignant glioma Cancer Research 2002 62 12 3347 3350 (Pubitemid 34651375)
126. Prins R. M., Cloughesy T. F., Liau L. M., Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate New England Journal of Medicine 2008 359 5 539 541
127. Mitchell D. A., Xie W., Schmittling R., Learn C., Friedman A., McLendon R. E., Sampson J. H., Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma Neuro-Oncology 2008 10 1 10 18 (Pubitemid 351250896)
128. Bao L., Dunham K., Stamer M., Mulieri K. M., Lucas K. G., Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation Biology of Blood and Marrow Transplantation 2008 14 10 1156 1162
129. Bao L., Sun Q., Lucas K. G., Rapid generation of CMV pp65-specific T cells for immunotherapy Journal of Immunotherapy 2007 30 5 557 561 (Pubitemid 46988089)
130. Yao J., Bechter C., Wiesneth M., Hrter G., Gtz M., Germeroth L., Guillaume P., Hasan F., Von Harsdorf S., Mertens T., Michel D., Dhner H., Bunjes D., Schmitt M., Schmitt A., Multimer staining of cytomegalovirus phosphoprotein 65-specific T cells for diagnosis and therapeutic purposes: a comparative study Clinical Infectious Diseases 2008 46 10 e96 e105 (Pubitemid 351706755)
131. Schmitt A., Tonn T., Busch D. H., Grigoleit G. U., Einsele H., Odendahl M., Germeroth L., Ringhoffer M., Ringhoffer S., Wiesneth M., Greiner J., Michel D., Mertens T., Rojewski M., Marx M., Von Harsdorf S., Dhner H., Seifried E., Bunjes D., Schmitt M., Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8 + T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation Transfusion 2011 51 3 591 599
132. Fontenot J. D., Rasmussen J. P., Gavin M. A., Rudensky A. Y., A function for interleukin 2 in Foxp3-expressing regulatory T cells Nature Immunology 2005 6 11 1142 1151 (Pubitemid 41541792)
133. El Andaloussi A., Lesniak M. S., An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme Neuro-Oncology 2006 8 3 234 243 (Pubitemid 46542648)
134. Fecci P. E., Mitchell D. A., Whitesides J. F., Xie W., Friedman A. H., Archer G. E., Herndon J. E., Bigner D. D., Dranoff G., Sampson J. H., Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma Cancer Research 2006 66 6 3294 3302
135. Heimberger A. B., Abou-Ghazal M., Reina-Ortiz C., Yang D. S., Sun W., Qiao W., Hiraoka N., Fuller G. N., Incidence and prognostic impact of FoxP3 + regulatory T cells in human gliomas Clinical Cancer Research 2008 14 16 5166 5172
136. Annunziato F., Cosmi L., Liotta F., Maggi E., Romagnani S., The phenotype of human Th17 cells and their precursors, the cytokines that mediate their differentiation and the role of Th17 cells in inflammation International Immunology 2008 20 11 1361 1368
137. Wan Y. Y., Flave R. A. I I, How diverseCD4 effector T cells and their functions Journal of Molecular Cell Biology 2009 1 1 20 36
138. Muranski P., Boni A., Antony P. A., Cassard L., Irvine K. R., Kaiser A., Paulos C. M., Palmer D. C., Touloukian C. E., Ptak K., Gattinoni L., Wrzesinski C., Hinrichs C. S., Kerstann K. W., Feigenbaum L., Chan C. C., Restifo N. P., Tumor-specific Th17-polarized cells eradicate large established melanoma Blood 2008 112 2 362 373
139. Wainwright D. A., Sengupta S., Han Y., Ulasov I. V., Lesniak M. S., The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human gliom PLoS ONE 2010 5 10
140. Rodrigues J. C., Gonzalez G. C., Zhang L., Ibrahim G., Kelly J. J., Gustafson M. P., Lin Y., Dietz A. B., Forsyth P. A., Yong V. W., Parney I. F., Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties Neuro-Oncology 2010 12 4 351 365
141. Raychaudhuri B., Rayman P., Ireland J., Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma Neuro-Oncology 2011 13 6 591 599
142. Ghebeh H., Bakr M. M., Dermime S., Cancer stem cell immunotherapy: the right bullet for the right target Hematology/Oncology and Stem Cell Therapy 2008 1 1 1 2
143. Bao S., Wu Q., McLendon R. E., Hao Y., Shi Q., Hjelmeland A. B., Dewhirst M. W., Bigner D. D., Rich J. N., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response Nature 2006 444 7120 756 760 (Pubitemid 44949604)
144. Liu G., Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I. R., Lu L., Irvin D., Black K. L., Yu J. S., Analysis of gene expression and chemoresistance of CD133 + cancer stem cells in glioblastoma Molecular Cancer 2006 5, article 67
145. Singh S. K., Clarke I. D., Terasaki M., Bonn V. E., Hawkins C., Squire J., Dirks P. B., Identification of a cancer stem cell in human brain tumors Cancer Research 2003 63 18 5821 5828 (Pubitemid 37187480)
146. Prestegarden L., Svendsen A., Wang J., Sleire L., Skaftnesmo K. O., Bjerkvig R., Yan T., Askland L., Persson A., Sakariassen P.., Enger P.., Glioma cell populations grouped by different cell type markers drive brain tumor growth Cancer Research 2010 70 11 4274 4279
147. Pellegatta S., Poliani P. L., Corno D., Menghi F., Ghielmetti F., Suarez-Merino B., Caldera V., Nava S., Ravanini M., Facchetti F., Bruzzone M. G., Finocchiaro G., Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas Cancer Research 2006 66 21 10247 10252 (Pubitemid 44799739)
148. Wang R., Chadalavada K., Wilshire J., Kowalik U., Hovinga K. E., Geber A., Fligelman B., Leversha M., Brennan C., Tabar V., Glioblastoma stem-like cells give rise to tumour endothelium Nature 2010 468 7325 829 835
149. Ricci-Vitiani L., Pallini R., Biffoni M., Todaro M., Invernici G., Cenci T., Maira G., Parati E. A., Stassi G., Larocca L. M., De Maria R., Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells Nature 2010 468 7325 824 830
150. Lake R. A., Robinson B. W. S., Immunotherapy and chemotherapyapractical partnership Nature Reviews Cancer 2005 5 5 397 405
151. Bourquin C., Schreiber S., Beck S., Hartmann G., Endres S., Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer International Journal of Cancer 2006 118 11 2790 2795 (Pubitemid 43673358)
152. Kim C. H., Woo S. J., Park J. S., Kim H. S., Park M. Y., Park S. D., Hong Y. K., Kim T. G., Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma Immunology 2007 122 4 615 622
153. Xu X., Stockhammer F., Schmitt A., Therapeutical doses of temozolomide do not impair the function of dendritic cells and CD8 + T cells International Journal of Oncology 40 3 764 772